Lung Cancer | Specialty

Clinical Presentation of Squamous NSCLC

March 3rd 2016

Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial

March 1st 2016

Second- or third-line treatment with tremelimumab monotherapy failed to improve overall survival compared with placebo for patients with unresectable malignant mesothelioma.

Peregrine Stops Phase III Trial of Bavituximab in NSCLC

February 26th 2016

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with non–small cell lung cancer has been halted following a futility analysis.

Expert Discusses Translating EGFR Mutation Status Into Action in NSCLC

February 24th 2016

Mark Socinski, MD, discusses the three generations of drugs are now available to treat patients with EGFR-mutant non–small cell lung cancer, and mutation testing for patients diagnosed with advanced or metastatic disease has been incorporated into clinical practice guidelines.

Dr. Filosso on Future of Treating Patients With Lung NETs

February 16th 2016

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.

Immunotherapy Continues Rapid Advance in NSCLC

February 16th 2016

Naiyer Rizvi, MD, discusses the role of PD-L1 testing, which PD-1/PD-L1 agents have the most potential, and what is on the horizon for the use of immunotherapies in non-small cell lung cancer.

Dr. Martins on Patient Selection for Nivolumab in NSCLC

February 15th 2016

Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).

Combining Therapies with Antiangiogenic Antibodies

February 15th 2016

Ramucirumab for Squamous or Nonsquamous Lung Cancer

February 15th 2016

Use of Bevacizumab for Lung Cancer

February 15th 2016

Therapeutic Targeting Against Abnormal Tumor Vasculature

February 15th 2016

Dysregulated Angiogenesis in Cancer

February 15th 2016

PD-L1/CTLA-4 Dual Blockade Shows Promise in NSCLC

February 12th 2016

A combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti–CTLA-4 agent tremelimumab induced a response rate of 23% in patients with advanced non–small cell lung cancer.

FDA Schedules ODAC Meeting for Rociletinib in NSCLC

February 12th 2016

The FDA has scheduled an ODAC advisory hearing for April 12, 2016, to discuss the new drug application for rociletinib as a treatment for patients with metastatic EGFR T790M-mutated non–small cell lung cancer.

Sequencing of Therapies in EGFR-Mutant NSCLC

February 11th 2016

Mechanisms of Resistance to Upfront EGFR-Targeted Therapy

February 11th 2016

EGFR Mutations and Targeted Therapy in NSCLC

February 11th 2016

EGFR TKIs for Upfront Treatment of NSCLC

February 11th 2016

Pembrolizumab Emerges as a Potent Treatment in NSCLC

February 11th 2016

The role of immunotherapy is emerging as an effective, and in some cases, dramatic treatment in the non-small cell lung cancer landscape.

Dr. Ramalingam on Emerging Combination Regimens in NSCLC

February 10th 2016

Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.